Genscript Biotech Corporation
GNNSF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $519 | $33 | $561 | $449 |
| % Growth | 1,466.6% | -94.1% | 25.1% | – |
| Cost of Goods Sold | $198 | $68 | $254 | $214 |
| Gross Profit | $321 | -$35 | $307 | $235 |
| % Margin | 61.8% | -105.3% | 54.7% | 52.3% |
| R&D Expenses | $31 | -$183 | $237 | $226 |
| G&A Expenses | $63 | -$6 | $120 | $107 |
| SG&A Expenses | $110 | -$19 | $221 | $202 |
| Sales & Mktg Exp. | $48 | -$9 | $97 | $93 |
| Other Operating Expenses | $0 | $7 | -$0 | -$21 |
| Operating Expenses | $142 | -$195 | $458 | $407 |
| Operating Income | $179 | $173 | -$151 | -$172 |
| % Margin | 34.5% | 523.9% | -26.9% | -38.4% |
| Other Income/Exp. Net | -$179 | $0 | -$55 | $66 |
| Pre-Tax Income | -$0 | $35 | -$206 | -$105 |
| Tax Expense | $24 | -$7 | $10 | $3 |
| Net Income | -$25 | $3,137 | -$175 | -$2 |
| % Margin | -4.9% | 9,473% | -31.2% | -0.4% |
| EPS | -0.012 | 1.48 | -0.083 | -0.001 |
| % Growth | -100.8% | 1,889.6% | -9,088.9% | – |
| EPS Diluted | -0.012 | 1.44 | -0.083 | -0.001 |
| Weighted Avg Shares Out | 1,180 | 2,121 | 2,117 | 2,099 |
| Weighted Avg Shares Out Dil | 2,156 | 2,178 | 2,117 | 2,099 |
| Supplemental Information | – | – | – | – |
| Interest Income | $10 | $59 | $88 | $47 |
| Interest Expense | $9 | $21 | $29 | $15 |
| Depreciation & Amortization | $30 | $28 | $33 | $39 |
| EBITDA | $209 | $188 | -$118 | -$52 |
| % Margin | 40.3% | 567.6% | -21% | -11.5% |